Update On Antares Pharma, Post Complete Response Letter
- The U.S Food and Drug Administration issued a CRL to Antares Pharma on the 20th Oct in regard to their drug: XYOSTED.
- Concerns about blood pressure and psychological side effects emerged.
- Here we evaluate possible outcomes.
Guest post by Jennifer Chin. The views and opinions expressed in this article are those of the author and do not necessarily reflect the position of Integer Investments.
To read the full article click here.